Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6985786 | 0.98 | ALDH1A1 (0.52) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL11240940 | 0.98 | ALDH1A1 (0.52) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL10172837 | 0.93 | ALDH1A1 (0.52) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL14615761 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL11394476 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL11397955 | 0.91 | ALDH1A1 (0.50) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL47547 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL14052549 | 0.84 | ALDH1A1 (0.44) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL11643592 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL14515368 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CA2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007011972-A2 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | INVERSEON, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| EP-0324692-B1 | PROCESS FOR THE PREPARATION OF HYDROXYALKYLATING AGENTS, THE AGENTS AS PREPARED AND THEIR USE | RHONE-POULENC SANTE (FR) | 1992-11-25 | — | — | EP | claimed |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | KIORA PHARMACEUTICALS PTY LTD (AU) | 2024-10-31 | — | — | US | disclosed |
| US-20230357451-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230293576-A1 | ANTIVIRAL POLYMERS | THE UNIVERSITY OF MANCHESTER (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-3183295-B1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023046710-A1 | FLOW BATTERIES WITH A NEGOLYTE BASED ON VIOLOGEN AND A HYDROALCOHOLIC SOLVENT | IFP Energies Nouvelles (FR) | 2023-03-30 | — | — | WO | disclosed |
| US-20230002513-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| US-7399349-B2 | Sheet for ink jet recording, ink for ink jet recording, manufacturing method of ink for ink jet recording, ink set for ink jet recording, and ink jet recording method | FUJIFILM CORPORATION (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7393094-B2 | Ink for inkjet, ink set for inkjet, and inkjet recording method | FUJIFILM CORPORATION (JP) | 2008-07-01 | — | — | US | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-20070224536-A1 | SILVER HALIDE PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL | HIRANO MITSUNORI | 2007-09-27 | — | — | US | disclosed |
| US-20070120920-A1 | Ink for inkjet, ink set for inkjet, and inkjet recording method | FUJIFILM CORPORATION (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070104993-A1 | single or multi- walled carbon nanotubes; improved ionic conductivity and suppresses cross-over of methanol | SAMSUNG SDI CO., LTD. (KR) | 2007-05-10 | — | — | US | disclosed |
| US-20070104993-A1 | single or multi- walled carbon nanotubes; improved ionic conductivity and suppresses cross-over of methanol | SAMSUNG SDI CO., LTD. (KR) | 2007-05-10 | — | — | US | disclosed |
| WO-2007011972-A2 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES | INVERSEON, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293576-A1 | ANTIVIRAL POLYMERS | MAVS, EIF2AK2, ZC3HAV1 | ALDH1A1 3162/4885CA2 4493/4885CHRM5 4846/4885 |
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | PDE6C, ALDH1A2, PDE6D | ALDH1A1 572/4885CA2 982/4885CHRM5 1195/4885 |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | ALDH1A1 2123/4885CA2 769/4885CHRM5 1672/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | ALDH1A1 4018/4885CA2 2294/4885CHRM5 2637/4885 |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | TPMT, GSTP1, ALB | ALDH1A1 1546/4885CA2 917/4885CHRM5 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.